









市场行情
/
股票
/
nasdaq-pvla
/

Palvella Therapeutics Inc

PVLA

103.370USD

-2.460-2.32%

收盘 12/26, 16:00（美东）报价延迟15分钟

1.15B总市值

亏损市盈率 TTM



Palvella Therapeutics Inc

103.370

-2.460-2.32%

概览公司财务分析

概览

公司

财务

分析

关于 Palvella Therapeutics Inc 公司

Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. The Company is developing a pipeline of product candidates based on its patented QTORIN platform, with an initial focus on serious, rare genetic skin diseases, many of which are lifelong in nature. Its QTORIN product candidates are developed to accommodate the cargo at high concentrations in order to drive sufficient drug to its target deep in the epidermis and dermis. The Company's lead product candidate, QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin), is being evaluated in the Phase III SELVA clinical trial in microcystic lymphatic malformations and the Phase II TOIVA clinical trial in cutaneous venous malformations.

Palvella Therapeutics Inc简介



公司代码PVLA

公司名称Palvella Therapeutics Inc

上市日期Dec 18, 2014

CEOKaupinen (Wesley H)

员工数量14

证券类型Ordinary Share

年结日Dec 18

公司地址353 W. Lancaster Avenue

城市WAYNE

上市交易所NASDAQ OMX - NASDAQ BASIC

国家United States of America

邮编19087

电话14842531461

网址https://palvellatx.com/

公司代码PVLA

上市日期Dec 18, 2014

CEOKaupinen (Wesley H)

Palvella Therapeutics Inc公司高管



名称

名称/职务

职务

持股

持股变动

Mr. George M. Jenkins

Independent Chairman of the Board

196.69K

+2.60%

Ms. Elaine J. Heron

Independent Director

51.29K

Mr. Christopher P. (Chris) Kiritsy

Independent Director

250.00

Ms. Kathleen Goin

Chief Operating Officer

Mr. Wesley H. (Wes) Kaupinen

President, Chief Executive Officer, Founder, Director

Mr. Matthew E. Korenberg

Chief Financial Officer

Mr. Todd C. Davis

Independent Director

Mr. Tadd S. Wessel

Independent Director

Dr. David W. Osborne, Ph.D.

Chief Innovation Officer

Dr. Jeffrey (Jeff) Martini, Ph.D.

Chief Scientific Officer

名称

名称/职务

职务

持股

持股变动

Mr. George M. Jenkins

Independent Chairman of the Board

196.69K

+2.60%

Ms. Elaine J. Heron

Independent Director

51.29K

Mr. Christopher P. (Chris) Kiritsy

Independent Director

250.00

Ms. Kathleen Goin

Chief Operating Officer

Mr. Wesley H. (Wes) Kaupinen

President, Chief Executive Officer, Founder, Director

Mr. Matthew E. Korenberg

Chief Financial Officer

收入明细

由于公司未披露，未能获取相关数据

由于公司未披露，未能获取相关数据

业务

地区

由于公司未披露，未能获取相关数据

股东统计

更新时间: 11月17日周一

持股股东

股东类型

持股股东

占比

Kaupinen (Wesley H.)

13.58%

BVF Partners L.P.

9.81%

Suvretta Capital Management, LLC

6.95%

Frazier Life Sciences Management, L.P.

6.10%

Integrated Finance Group

4.73%

其他

58.83%

持股股东

占比

Kaupinen (Wesley H.)

13.58%

BVF Partners L.P.

9.81%

Suvretta Capital Management, LLC

6.95%

Frazier Life Sciences Management, L.P.

6.10%

Integrated Finance Group

4.73%

其他

58.83%

股东类型

持股股东

占比

Hedge Fund

29.48%

Investment Advisor/Hedge Fund

17.41%

Individual Investor

16.63%

Investment Advisor

13.20%

Private Equity

9.44%

Other Insider Investor

4.73%

Research Firm

2.39%

Venture Capital

1.87%

Bank and Trust

0.07%

其他

4.78%

机构持股



更新时间: 10月1日周三

报告期

机构数

持股数

持股占比

持股变动

2025Q3

145

6.92M

62.61%

+1.10M

2025Q2

113

8.02M

72.53%

+1.47M

2025Q1

119

7.23M

65.51%

+2.66M

2024Q4

118

6.14M

54.71%

+5.00M

2024Q3

118

806.99K

64.03%

-218.37K

2024Q2

120

474.51K

38.85%

-479.71K

2024Q1

135

564.53K

48.12%

-430.81K

2023Q4

149

574.40K

48.95%

-409.12K

2023Q3

161

703.90K

61.81%

-282.90K

2023Q2

173

831.24K

82.60%

-68.86K

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

Kaupinen (Wesley H.)

1.61M

14.53%

Apr 14, 2025

BVF Partners L.P.

696.55K

6.3%

Jun 30, 2025

Suvretta Capital Management, LLC

714.46K

6.46%

Jun 30, 2025

Frazier Life Sciences Management, L.P.

722.40K

6.53%

+32.39K

+4.69%

Jun 30, 2025

Integrated Finance Group

559.95K

5.06%

+559.95K

Apr 14, 2025

The Vanguard Group, Inc.

163.81K

1.48%

+25.38K

+18.33%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

409.73K

3.7%

+298.98K

+269.95%

Jun 30, 2025

Woodline Partners LP

445.62K

4.03%

+251.45K

+129.50%

Jun 30, 2025

持股ETF



更新时间: 12月2日周二

机构名称

占比

Invesco Dorsey Wright SmallCap Momentum ETF

0.51%

ALPS Medical Breakthroughs ETF

0.37%

iShares Micro-Cap ETF

0.11%

Vanguard US Momentum Factor ETF

0.1%

iShares Russell 2000 Growth ETF

0.03%

Global X Russell 2000 ETF

0.02%

Invesco Russell 2000 Dynamic Multifactor ETF

0.02%

ProShares Hedge Replication ETF

0.02%

iShares Russell 2000 ETF

0.02%

Proshares Ultra Russell 2000

0.02%

Invesco Dorsey Wright SmallCap Momentum ETF

占比0.51%

ALPS Medical Breakthroughs ETF

占比0.37%

iShares Micro-Cap ETF

占比0.11%

Vanguard US Momentum Factor ETF

占比0.1%

iShares Russell 2000 Growth ETF

占比0.03%

Global X Russell 2000 ETF

占比0.02%

Invesco Russell 2000 Dynamic Multifactor ETF

占比0.02%

ProShares Hedge Replication ETF

占比0.02%

iShares Russell 2000 ETF

占比0.02%

Proshares Ultra Russell 2000

占比0.02%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

类型

比率

Apr 18, 2024

Merger

80→1

Apr 18, 2024

Merger

80→1

Apr 18, 2024

Merger

80→1

Apr 18, 2024

Merger

80→1

公告日期

类型

比率

Apr 18, 2024

Merger

80→1

Apr 18, 2024

Merger

80→1

Apr 18, 2024

Merger

80→1

Apr 18, 2024

Merger

80→1

常见问题

Palvella Therapeutics Inc的前五大股东是谁？



Palvella Therapeutics Inc 的前五大股东如下：
Kaupinen (Wesley H.)持有股份：1.61M，占总股份比例：14.53%。
BVF Partners L.P.持有股份：696.55K，占总股份比例：6.30%。
Suvretta Capital Management, LLC持有股份：714.46K，占总股份比例：6.46%。
Frazier Life Sciences Management, L.P.持有股份：722.40K，占总股份比例：6.53%。
Integrated Finance Group持有股份：559.95K，占总股份比例：5.06%。